Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,115.0
-11.1 (-0.35%)

 

  • STI Straits Times Index
    3,115.0
    -11.1 (-0.35%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,599.2
    -1.1 (-0.07%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    25,734.2
    238.8 (0.94%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,823.8
    8.0 (0.29%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    20,418.8
    13.2 (0.06%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,286.7
    29.1 (0.46%)
    Index delayed 10 minutes
  • KOR KOSPI
    1,927.2
    -11.2 (-0.58%)
    Index delayed 20 minutes
  • XAO XAO
    6,485.9
    -4.9 (-0.08%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 881.1M
  • Value: 1,121.3M
  • Rise: 154
  • Fall: 151
  • Unch: 532

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
YZJ Shipbldg SGD0.990+0.130
LionGold0.001-
ThaiBev0.885-0.020
KLW0.004-
ISR Capital^0.003-
Mapletree NAC Tr1.330+0.040
SingTel3.210-0.020
Seroja Inv^0.078+0.046
Genting Sing0.875+0.005
Synagie0.162+0.010

World Indices

World Indices
Name Last Change
Nasdaq 7,896.0 +129.4
HSI 25,734.2 +238.8
HSCEI 9,964.3 +60.9
Jakarta 6,286.7 +29.1
Nikkei 225 20,418.8 +13.2
SSE Comp 2,823.8 +8.0
Shanghai A 2,958.2 +8.4
Shanghai B 260.6 +1.7
PSE Comp 0.0
KOSPI 1,927.2 -11.2

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

Hyphens Pharma HYPHENS PHARMA INTL LIMITED
Quotes 10 Minutes Delayed. Updated at 16 Aug 2019 16:59
Last (SGD): 0.200 Change: - High: 0.200 Remarks: -
Change (%): - Low: 0.199
Open 0.199 Yesterday's Close 0.200
Buy Price 0.200 Sell Price 0.205
Buy Volume ('000) 20.0 Sell Volume ('000) 30.0
Cumulative Volume ('000) 82.7 Cumulative Value 16,512
Click to show Stock Prices chart

Key Statistics

EPS (SGD) a 0.01801 Trailing EPS (SGD) e 0.01687 NAV (SGD) b 0.1353
PE a 11.105 Trailing PE f 11.858 Price / NAV b 1.4782
Dividend (SGD) d 0.005492 Cash In Hand (SGD) g 0.0787 Issued & Paid-up Shares c 300,430,000
Dividend Yield (%) d 2.746 Price / Cash In Hand g 2.541 Treasury Shares h -
Beta - 75 Daysi 0.445 R-Squared - 75 Days(%)i 2.42 Market Cap (M) 60.086
Beta - 500 Daysi 0.331 R-Squared - 500 Days (%)i 1.00 Enterprise Value (M) 40.452
Piotroski F Score - Exchange Code 1J5 Par Value ( SGD ) n.a.
52 Weeks Volatility (%) 33.4096 6-Month VWAP 0.210 Free Float (%) 20.1
Under CPF Investment Scheme (CPFIS) No
Sector & Industry Wholesale and Retail Trade - Pharmaceuticals: Major
Category Classification Medical & Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 14 Aug 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand.
  9. Beta and R-Squared are calculated in relation to the market index (STI or KLCI) using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference Hyphens Pharma SGX 60.086 11.105 11.858 1.4782 2.746
Industry Medical & Biotechnology SGX 1,026.771 23.435 26.816 1.4299 1.835
Pharmaceuticals: Major SGX 40.365 10.437 22.582 1.1951 2.044
Local Peer Star Pharm^ SGX 20.644 8.879 - 0.7670 -
Global Peer JOHNSON & JOHNSON NYSE 346,681.371 22.663 21.227 5.7034 2.719
Global Peer NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD) NYSE 228,204.866 18.054 19.988 4.4375 1.866
Global Peer MERCK & CO INC NYSE 217,785.923 35.014 23.263 7.8808 2.369
Global Peer PFIZER INC NYSE 191,650.883 17.185 15.151 3.2183 4.117
Global Peer ASTRAZENECA SPON ADR EACH REP 0.50 ORD SHS NYSE 116,337.075 54.076 53.226 8.5870 2.984
Global Peer ELI LILLY AND COMPANY NYSE 106,699.655 33.014 25.631 38.3737 2.229
Global Peer SANOFI SPON ADS ECH REP 1/2 ORD EUR2 LEVEL II NASDAQ 104,831.076 20.574 25.487 1.6335 2.746
Global Peer GLAXOSMITHKLINE ADR EACH CNV INTO 2 ORD GBP0.25 NYSE 100,242.300 20.750 17.492 21.7938 5.063
Global Peer NOVO NORDISK A/S ADR-EACH CNV INTO 1 CLASS B DKK1 NYSE 96,219.850 15.737 16.757 - 2.201
Global Peer ABBVIE INC NYSE 95,258.466 16.839 23.291 -11.1205 6.132
Other Global Peers BRISTOL-MYERS SQUIBB CO (NYSE), TAKEDA PHARMACEUTICAL CO LTD SPON ADS EACH REP 0.5 ORD SHS (NYSE), HANSOH PHARMA (HKEx), WUXI APPTEC (HKEx), CHINARES PHARMA (HKEx), GRIFOLS SA SPON ADR EA REPR 1 ORD EUR0.10 (NASDAQ), ALLAKOS INC (NASDAQ), INNOVENT BIO-B (HKEx), JUNSHI BIO-B (HKEx), HUTCHISON CHINA MEDITECH SPON ADS EACH REPR 5 ORD SHS (NASDAQ), REATA PHARMACEUTICALS INC (NASDAQ), CMS (HKEx), BIOHAVEN PHARMACEUTICAL HLDG CO LTD (NYSE), AKCEA THERAPEUTICS INC (NASDAQ), APELLIS PHARMACEUTICALS INC (NASDAQ), CHINAGRANDPHARM (HKEx), TRICIDA INC (NASDAQ), G1 THERAPEUTICS IN (NASDAQ), RA PHARMACEUTICALS INC (NASDAQ), CSTONE PHARMA-B (HKEx), TURNING POINT THERAPEUTICS INC (NASDAQ), ORCHARD THERAPEUTICS PLC SPON ADS EACH REPR 1 ORD SHS (NASDAQ), PHIBRO ANIMAL HEALTH CORP (NASDAQ), ATHENEX INC (NASDAQ), GOSSAMER BIO INC (NASDAQ), ODONATE THERAPEUTICS LLC (NASDAQ), ZYMEWORKS INC (NYSE), Y-MABS THERAPEUTICS INC (NASDAQ), PETIQ INC (NASDAQ), PRINCIPIA BIOPHARMA INC (NASDAQ), CANSINOBIO-B (HKEx), UNITED LAB (HKEx), HUA MEDICINE-B (HKEx), QUANTERIX CORPORATION (NASDAQ), AKERO THERAPEUTICS INC (NASDAQ), KRYSTAL BIOTECH INC (NASDAQ), AMNEAL PHARMACEUTICALS INC (NYSE), KINIKSA PHARMACEUTICALS LTD (NASDAQ), FUSEN PHARM (HKEx), KARUNA THERAPEUTICS INC (NASDAQ), APTORUM GROUP LIMITED (NASDAQ), CRINETICS PHARMACEUTICALS INC (NASDAQ), IGBB (Bursa), BEYONDSPRING INC (NASDAQ), BIOSPECIFICS TECHNOLOGIES CORP (NASDAQ), MILESTONE PHARMACEUTICALS INC (NASDAQ), DOVA PHARMACEUTICALS INC (NASDAQ), OBSEVA SA (NASDAQ), AMAG PHARMACEUTICS INC (NASDAQ), EVOLUS INC (NASDAQ), TCR2 THERAPEUTICS INC (NASDAQ), AC IMMUNE SA (NASDAQ), PROVENTION BIO INC (NASDAQ), GRITSTONE ONCOLOGY INC (NASDAQ), AKORN INC (NASDAQ), XERIS PHARMACEUTICALS INC (NASDAQ), MIRUM PHARMACEUTICALS INC (NASDAQ), DAWNRAYS PHARMA (HKEx), FORTY SEVEN INC (NASDAQ), LANNETT CO INC (NYSE), KALEIDO BIOSCIENCES INC (NASDAQ), CYCLERION THERAPEUTICS INC (NASDAQ), UROVANT SCIENCES LTD (NASDAQ), VERRICA PHARMACEUTICALS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), PHASEBIO PHARMACEUTICALS INC (NASDAQ), FULCRUM THERAPEUTICS INC (NASDAQ), CONSTELLATION PHARMACEUTICALS INC (NASDAQ), SUTRO BIOPHARMA INC (NASDAQ), EVELO BIOSCIENCES INC (NASDAQ), AFT PHARMACEUTICALS LTD (ASX), SPERO THERAPEUTICS INC (NASDAQ), NC HEALTHCARE (HKEx), LOGICBIO THERAPEUTICS INC (NASDAQ), SOL GEL TECHNOLOGIES LTD (NASDAQ), OSMOTICA PHARMACEUTICALS PLC (NASDAQ), MUSTANG BIO INC (NASDAQ), HOOKIPA PHARMA INC (NASDAQ), EMMAUS LIFE SCIENCES INC NEW (NASDAQ), EYEPOINT PHARMACEUTICALS INC (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), ARCTURUS THERAPEUTICS HOLDINGS INC (NASDAQ), IMMUNIC INC (NASDAQ), KALA PHARMACEUTICALS INC (NASDAQ), IDEAYA BIOSCIENCES INC (NASDAQ), CORVUS PHARMACEUTICALS INC (NASDAQ), TYME TECHNOLOGIES INC (NASDAQ), Merck Tbk. (IDX), LIQUIDIA TECHNOLOGIES INC (NASDAQ), SCPHARMACEUTICALS INC (NASDAQ), AGEX THERAPEUTICS INC (NYSE American), GAMIDA CELL LTD (NASDAQ), ASSERTIO THERAPEUTICS INC (NASDAQ), CHECKPOINT THERAPEUTICS INC (NASDAQ), Phapros Tbk. (IDX), CHARMACY PHAR (HKEx), ETON PHARMACEUTICALS INC (NASDAQ), AVENUE THERAPEUTICS INC (NASDAQ), AQUESTIVE THERAPEUTICS INC (NASDAQ), MILLENDO THERAPEUTICS INC (NASDAQ), ALLENA PHARMACEUTICALS INC (NASDAQ), TREVI THERAPEUTICS INC (NASDAQ), MENLO THERAPEUTICS INC (NASDAQ), NEUBASE THERAPEUTICS INC (NASDAQ), OVID THERAPEUTICS INC (NASDAQ), ARIDIS PHARMACEUTICAL INC (NASDAQ), PALLA PHARMA LTD (ASX), ONCTERNAL THERAPEUTICS INC (NASDAQ), SPRING BANK PHARMACEUTICALS INC (NASDAQ), MEDLAB CLINICAL LIMITED (ASX), NOVAN INC (NASDAQ), KOTRA (Bursa), CHINA SXT PHARMACEUTICALS INC (NASDAQ), EYENOVIA INC (NASDAQ), NEP INTERLONG (HKEx), HOTH THERAPEUTICS INC (NASDAQ), MOLECULIN BIOTECH INC (NASDAQ), CLEARSIDE BIOMEDICAL INC (NASDAQ), BIOHLDG (Bursa), CRESO PHARMA LTD (ASX), BIONDVAX PHARMACEUTICALS SPON ADS REP 40 ORD SHS (NASDAQ), MMJ GROUP HOLDINGS LTD (ASX), TELIGENT INC NEW (NASDAQ), AKARI THERAPEUTICS PLC SPON ADR EACH REPR 100 ORD (NASDAQ), NOXOPHARM LTD (ASX), NOVA (Bursa), PDS BIOTECHNOLOGY CORPORATION (NASDAQ), SINOLIFE UTD (HKEx), EDESA BIOTECH INC (NASDAQ), ENTERA BIO LTD (NASDAQ), ZOMEDICA PHARMACEUTICALS CORP (NYSE American), AERPIO PHARMACEUTICALS INC (NASDAQ), SIENNA BIOPHARMACEUTICALS INC (NASDAQ), EXOPHARM LTD (ASX), CITIUS PHARMACEUTICALS INC (NASDAQ), ESSA PHARMA INC (NASDAQ), ACER THERAPEUTICS INC (NASDAQ), AILERON THERAPEUTICS INC (NASDAQ), ADIAL PHARMACEUTICALS INC (NASDAQ), RECCE PHARMACEUTICALS LTD (ASX), KITOV PHARMA LTD SPON ADS EACH REP 1 ORD SHS (NASDAQ), GENPREX INC (NASDAQ), FARMAFORCE LTD (ASX), NOVUS THERAPEUTICS INC (NASDAQ), SUDA PHARMACEUTICALS LTD (ASX), GEMPHIRE THERAPEUTICS INC (NASDAQ), TITAN PHARMACEUTICAL INC (NASDAQ), RACE ONCOLOGY LTD (ASX), FIJI KAVA LTD (ASX), Merck Sharp Dohme Pharma Tbk. (IDX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days ---
10 Days --0.010
-4.76 %
20 Days --0.020
-9.09 %
Medium Term Return 3 Months ---
6 Months 0.006+0.010
+8.42 %
1 Year 0.006-0.010
-1.90 %
Annualised Return Annualised --
-1.90 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 0.160 - 0.240 Change From 1 Year Low +0.040 % Change From 1 Year Low (%) +25.00
Change From 1 Year High -0.040 % Change From 1 Year High (%) -16.67
2 Years Range 0.160 - 0.305 Change From 2 Years Low +0.040 % Change From 2 Years Low (%) +25.00
Change From 2 Years High -0.105 % Change From 2 Years High (%) -34.43
5 Years Range 0.160 - 0.305 Change From 5 Years Low +0.040 % Change From 5 Years Low (%) +25.00
Change From 5 Years High -0.105 % Change From 5 Years High (%) -34.43
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Hyphens Pharma International Limited and its subsidiaries (the "Group") is one of Singapores leading specialty pharmaceutical and consumer healthcare groups leveraging on its diverse footprint in ASEAN countries. The Group has a direct presence in five ASEAN countries, namely, Singapore, Vietnam, Malaysia, Indonesia and the Philippines, supplemented by a marketing and distribution network covering five additional jurisdictions, namely, Hong Kong, Myanmar, Brunei, Cambodia and Oman. Singapore is the Groups regional headquarters, where its strategic planning, finance, regulatory affairs, research and development, legal, business development and logistics operations are based.The Groups core business comprises the following segments: specialty pharma principals, proprietary brands, and medical hypermart and digital. Besides marketing and selling a range of specialty pharmaceutical products in selected ASEAN countries through exclusive distributorship or licensing and supply agreements with brand principals mainly from Europe and the United States, the Group also develops, markets and sells its own proprietary range of dermatological products and health supplement products. In addition, the Group operates a medical hypermart for healthcare professionals, healthcare institutions and retail pharmacies, to supply pharmaceutical products and medical supplies.

IPO Performance

Listing Date 18 May 2018 Full Subscription Rate (x) 17.91
No of Placement Shares (M) 23.79 No of Public Offer Shares (M) 3.00 Public Offer Subscription Rate (x) 151.99
IPO Price (SGD) a 0.260 First Day Close (SGD) a 0.275 First Week Close (SGD) a 0.260
Current vs IPO Price (%) -23.08 First Day Gain (%) +5.77 First Week Gain (%) -
Notes:
  1. Adjusted for the following: 23,790,000 Placement Shares do not include the 2,810,000 Reserved Shares.

Reports Download

Report Type Financial Year Ended Download
Annual Report
Annual Report 2018 Dec 2018 Part 1(7.14 MB)
IPO Prospectus
IPO Prospectus 2018 May 2018 Part 1(2.57 MB)
Part 2(0.27 MB)

Historical Price Data

Date Open High Low Close Volume VWAP
16 Aug 2019 0.199 0.200 0.199 0.200 82,700 0.1997
15 Aug 2019 0.200 0.200 0.200 0.200 50,000 0.2000
14 Aug 2019 0.200 0.200 0.200 0.200 70,000 0.2000
13 Aug 2019 0.200 0.200 0.200 0.200 - -
08 Aug 2019 0.200 0.200 0.200 0.200 186,200 0.2000
07 Aug 2019 0.205 0.205 0.200 0.200 50,200 0.2050
06 Aug 2019 0.200 0.205 0.199 0.200 214,000 0.2008
05 Aug 2019 0.200 0.200 0.200 0.200 20,000 0.2000
02 Aug 2019 0.210 0.210 0.210 0.210 36,400 0.2100
01 Aug 2019 0.210 0.210 0.205 0.210 301,500 0.2081
31 Jul 2019 0.215 0.215 0.210 0.210 389,500 0.2113
30 Jul 2019 0.215 0.215 0.215 0.215 275,000 0.2150
29 Jul 2019 0.220 0.220 0.215 0.220 141,900 0.2154
26 Jul 2019 0.220 0.220 0.220 0.220 - -
25 Jul 2019 0.220 0.220 0.220 0.220 16,000 0.2200
24 Jul 2019 0.225 0.225 0.220 0.220 244,200 0.2202
23 Jul 2019 0.225 0.225 0.220 0.225 51,000 0.2245
22 Jul 2019 0.220 0.230 0.220 0.225 174,100 0.2224
19 Jul 2019 0.215 0.225 0.215 0.220 194,000 0.2207
18 Jul 2019 0.220 0.230 0.215 0.215 839,300 0.2211
17 Jul 2019 0.220 0.220 0.215 0.215 144,300 0.2159
16 Jul 2019 0.210 0.225 0.210 0.220 1,258,000 0.2184
Summary
Current 2 Weeks
(01 Aug 2019 to 16 Aug 2019)
0.210 0.210 0.199 0.200 1,011,000 -
Previous 2 Weeks
(18 Jul 2019 to 31 Jul 2019)
0.220 0.230 0.199 0.210 2,325,000 -
4 Weeks from
(20 Jun 2019 to 17 Jul 2019)
0.197 0.210 0.197 0.215 5,873,600 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.